Evidence map›Paper›PMID 35029877›Full record

ArticleMedicine2022

Analysis of the active components and mechanism of Shufeng Jiedu capsule against COVID-19 based on network pharmacology and molecular docking.

Jimilihan Simayi, Maimaitiming Nuermaimaiti, Ainiwaer Wumaier, Nawaz Khan, Maierdan Yusufu, Muhadaisi Nuer, Nulibiya Maihemuti, Bayinsang, Kaysar Adurusul, Wenting Zhou

Abstract read
In one paragraph

Article in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jimilihan SimayiDepartment of Pharmacology, Xinjiang Medical University, Urumqi, Xinjiang, China.
Maimaitiming NuermaimaitiTraditional Uighur Medicine Department, Xinjiang Medical University, Urumqi, Xinjiang, China.
Ainiwaer WumaierDepartment of Pharmacology, Xinjiang Medical University, Urumqi, Xinjiang, China.
Nawaz KhanDepartment of Pharmacology, Xinjiang Medical University, Urumqi, Xinjiang, China.
Maierdan YusufuDepartment of Pharmacology, Xinjiang Medical University, Urumqi, Xinjiang, China.
Muhadaisi NuerDepartment of Pharmacology, Xinjiang Medical University, Urumqi, Xinjiang, China.
Nulibiya MaihemutiDepartment of Pharmacology, Xinjiang Medical University, Urumqi, Xinjiang, China.
BayinsangDepartment of Pharmacology, Xinjiang Medical University, Urumqi, Xinjiang, China.
Kaysar AdurusulDepartment of Pharmacology, Xinjiang Medical University, Urumqi, Xinjiang, China.
Wenting ZhouDepartment of Pharmacology, Xinjiang Medical University, Urumqi, Xinjiang, China.ORCID 0000-0003-2610-7634

Funding

ational Natural Science Foundation of China 81660696Xinjiang Medical University Postdoctoral Research Startup Fund Project 170401Xinjiang Uygur Autonomous Region Administration of Traditional Chinese Medicine of Ethnic Medicine-Xinjiang Traditional Chinese Medicine of Ethnic Medicine and New Medicine R & D Project 2017-02-05
6 · The paper itself

Abstract

abstractThis study investigates the active components and mechanism of Shufeng Jiedu Capsules (SFJDC) against novel coronavirus through network pharmacology and molecular docking.The TCMSP, TCMID, and BATMAN-TCM databases were used to retrieve the components of SFJDC. The active components were screened by ADME (absorption, distribution, metabolism, and excretion) parameters, and identified by Pubchem, Chemical Book, and ChemDraw softwares. The molecular docking ligands were constructed. SARS Coronavirus-2 Major Protease (SARS-CoV-2-Mpro) and angiotension converting enzyme 2 (ACE2) were used as molecular docking receptors. AutoDock software was used for molecular docking. Cytoscape 3.7.1 software was used to generate an herbs-active components-targets network. Gene Ontology gene function and Kyoto Encyclopedia of Genes and Genomes signal pathway analysis were performed by DAVID data.A total of 1244 components were identified from SFJDC, and 210 active components were obtained. Among them, 97 active components were used as docking ligands to dock with SARS-CoV-2-Mpro and ACE2. There were 48 components with good binding activity to SARS-CoV-2-Mpro. Ten active components (including 7-Acetoxy-2-methylisoflavone, Kaempferol, Quercetin, Baicalein, Glabrene, Glucobrassicin, Isoglycyrol, Wogonin, Petunidin, and Luteolin) combined with SARS-CoV-2-Mpro and ACE2 simultaneously. Among them, Kaempferol, Wogonin, and Baicalein showed higher binding activity. The herbs-active components-targets network contained 7 herbs, 10 active components, and 225 targets. The 225 target targets were involved in 653 biological processes of Gene Ontology analysis and 130 signal pathways (false discovery rate ≤ 0.01) of Kyoto Encyclopedia of Genes and Genomes analysis.The active components of SFJDC (such as Kaempferol, Wogonin, and Baicalein) may combine with ACE2 and act on multiple signaling pathways and targets to exert therapeutic effect on novel coronavirus.

Indexed as

COVID-19 Drug TreatmentNetwork PharmacologyAngiotensin-Converting Enzyme 2Drugs, Chinese HerbalHumansKaempferolsLigandsMolecular Docking SimulationSARS-CoV-2Angiotensin-Converting Enzyme 2Drugs, Chinese HerbalKaempferolsLigandsshufeng jiedu

Identifiers

PMID35029877
PMCPMC8735807

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.